BioCentury
ARTICLE | Clinical News

TH-302: Phase I/II data

July 1, 2013 7:00 AM UTC

An open-label, dose-escalation, U.S. Phase I/II trial showed that TH-302 plus Sutent sunitinib led to partial responses in 1 of 4 patients with gastrointestinal stromal tumors (GIST) and in 3 of 4 patients with renal cell carcinoma (RCC), including 2 confirmed partial responses. Patients received 50 mg Sutent plus 240 or 340 mg/m 2 TH-302 on days 8, 15 and 22 days. There was a dose-limiting toxicity (DLT) of stomatitis at the 340 mg/m 2 dose. The trial is enrolling up to 58 patients with advanced solid tumors, including pancreatic neuroendocrine tumors. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...